Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ) (HNSBF) Financial Performance & Income Statement Overview
Analyze Hansa Biopharma AB (publ) (HNSBF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Hansa Biopharma AB (publ) (HNSBF) Income Statement & Financial Overview
Review Hansa Biopharma AB (publ) HNSBF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $66.35M | $32.34M | $48.66M | $34.33M |
| Cost of Revenue | $20.53M | $13.49M | $11.38M | $40.53M |
| Gross Profit | $45.82M | $18.85M | $37.28M | -$6.19M |
| Gross Profit Ratio | $0.69 | $0.58 | $0.77 | -$0.18 |
| R&D Expenses | $64.26M | $101.44M | $79.62M | $87.28M |
| SG&A Expenses | $75.99M | $88.50M | $75.82M | $88.21M |
| Operating Expenses | $139.24M | $162.49M | $154.21M | $175.49M |
| Total Costs & Expenses | $159.76M | $175.98M | $165.59M | $216.01M |
| Interest Income | $86.16M | $3.84M | $13.26M | $5.97M |
| Interest Expense | $29.49M | $103.76M | $0.00 | $26.51M |
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $706750.00 |
| EBITDA | -$7.25M | -$169.83M | -$116.93M | -$181.41M |
| EBITDA Ratio | -$0.11 | -$5.25 | -$2.40 | -$5.28 |
| Operating Income | -$93.42M | -$143.64M | -$116.93M | -$181.68M |
| Operating Income Ratio | -$1.41 | -$4.44 | -$2.40 | -$5.29 |
| Other Income/Expenses (Net) | $56.68M | -$129.95M | $13.26M | -$26.25M |
| Income Before Tax | -$36.74M | -$273.59M | -$103.67M | -$207.93M |
| Income Before Tax Ratio | -$0.55 | -$8.46 | -$2.13 | -$6.06 |
| Income Tax Expense | $337000.00 | $2.83M | $126000.00 | -$14000.00 |
| Net Income | -$37.08M | -$276.42M | -$103.80M | -$207.94M |
| Net Income Ratio | -$0.56 | -$8.55 | -$2.13 | -$6.06 |
| EPS | -$0.55 | -$4.08 | -$1.53 | -$3.30 |
| Diluted EPS | -$0.55 | -$4.08 | -$1.53 | -$3.30 |
| Weighted Avg Shares Outstanding | $67.81M | $67.81M | $67.81M | $62.93M |
| Weighted Avg Shares Outstanding (Diluted) | $67.81M | $67.81M | $67.81M | $62.93M |
Over the last four quarters, Hansa Biopharma AB (publ) achieved steady financial progress, growing revenue from $34.33M in Q2 2024 to $66.35M in Q1 2025. Gross profit stayed firm with margins at 69% in Q1 2025 versus -18% in Q2 2024. Operating income totaled -$93.42M in Q1 2025, maintaining a -141% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$7.25M. Net income rose to -$37.08M, with EPS at -$0.55. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan